• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Should cytoreductive treatment be performed before transplantation in patients with high-risk myelodysplastic syndrome?

作者信息

Alessandrino Emilio Paolo, Della Porta Matteo Giovanni, Pascutto Cristiana, Bacigalupo Andrea, Rambaldi Alessandro

出版信息

J Clin Oncol. 2013 Jul 20;31(21):2761-2. doi: 10.1200/JCO.2012.48.0525. Epub 2013 Jun 17.

DOI:10.1200/JCO.2012.48.0525
PMID:23775971
Abstract
摘要

相似文献

1
Should cytoreductive treatment be performed before transplantation in patients with high-risk myelodysplastic syndrome?对于高危骨髓增生异常综合征患者，是否应在移植前进行减瘤治疗？
J Clin Oncol. 2013 Jul 20;31(21):2761-2. doi: 10.1200/JCO.2012.48.0525. Epub 2013 Jun 17.
2
Impact of azacitidine before allogeneic stem-cell transplantation for myelodysplastic syndromes: a study by the Société Française de Greffe de Moelle et de Thérapie-Cellulaire and the Groupe-Francophone des Myélodysplasies.异基因造血干细胞移植前应用阿扎胞苷治疗骨髓增生异常综合征：法国骨髓移植和细胞治疗学会与法语区骨髓增生异常综合征协作组研究
J Clin Oncol. 2012 Dec 20;30(36):4533-40. doi: 10.1200/JCO.2012.44.3499. Epub 2012 Oct 29.
3
Successful treatment of donor cell derived myelodysplastic syndrome with 5-azacytidine.5-氮杂胞苷成功治疗供体细胞衍生的骨髓增生异常综合征
Ann Biol Clin (Paris). 2017 Dec 1;75(6):713-714. doi: 10.1684/abc.2017.1293.
4
Tuning the rigging before sailing off into the stormy sea of stem cell transplants for patients with myelodysplastic syndromes.在驶入针对骨髓增生异常综合征患者的干细胞移植这片波涛汹涌的海域之前调整索具。
Biol Blood Marrow Transplant. 2012 Aug;18(8):1145-7. doi: 10.1016/j.bbmt.2012.05.004. Epub 2012 May 15.
5
Response to treatment with azacitidine in children with advanced myelodysplastic syndrome prior to hematopoietic stem cell transplantation.造血干细胞移植前，阿扎胞苷治疗晚期骨髓增生异常综合征患儿的疗效。
Haematologica. 2016 Dec;101(12):1508-1515. doi: 10.3324/haematol.2016.145821. Epub 2016 Aug 18.
6
Pretransplantation therapy with hypomethylating agents in patients with myelodysplastic syndromes receiving reduced-intensity conditioning regimens.接受减低强度预处理方案的骨髓增生异常综合征患者的移植前低甲基化药物治疗
Biol Blood Marrow Transplant. 2014 Sep;20(9):1260-1. doi: 10.1016/j.bbmt.2014.07.006. Epub 2014 Jul 11.
7
Mutational analysis in serial marrow samples during azacitidine treatment in patients with post-transplant relapse of acute myeloid leukemia or myelodysplastic syndromes.急性髓系白血病或骨髓增生异常综合征移植后复发患者接受阿扎胞苷治疗期间系列骨髓样本的突变分析。
Haematologica. 2017 Jun;102(6):e216-e218. doi: 10.3324/haematol.2016.162909. Epub 2017 Feb 16.
8
Salvage induction chemotherapy after azacitdine treatment failure in patients who received azacitidine as a bridge to allogeneic stem cell transplantation.接受阿扎胞苷作为异基因干细胞移植桥梁治疗失败后进行挽救性诱导化疗的患者。
Br J Haematol. 2014 Jul;166(2):303-6. doi: 10.1111/bjh.12844. Epub 2014 Mar 21.
9
First Steps Towards Successful Post-Transplantation Therapy for Myeloid Malignancies after Allogeneic Blood Stem Cell Transplantation.异基因造血干细胞移植后髓系恶性肿瘤成功移植后治疗的初步探索
Biol Blood Marrow Transplant. 2015 Oct;21(10):1703-4. doi: 10.1016/j.bbmt.2015.08.012. Epub 2015 Aug 12.
10
Dismal outcome of acute myeloid leukemia secondary to myelodysplastic syndrome and chronic myelomonocytic leukemia after azacitidine failure in a daily-life setting.在日常生活环境中，阿扎胞苷治疗失败后，继发于骨髓增生异常综合征和慢性粒单核细胞白血病的急性髓系白血病预后不佳。
Acta Haematol. 2015;133(1):64-6. doi: 10.1159/000363643. Epub 2014 Aug 14.

引用本文的文献

1
Social Media Insights Into Disease Burden in Patients and Caregivers of Myelodysplastic Syndrome: Subcohort Analysis of High-Risk Patients.社交媒体对骨髓增生异常综合征患者及其照料者疾病负担的洞察：高危患者亚组分析
J Med Internet Res. 2025 Aug 22;27:e65460. doi: 10.2196/65460.
2
Better pre-transplant treatment options for TP53-mutated MDS: cytoreductive or non-cytoreductive therapy?TP53 突变型骨髓增生异常综合征更好的移植前治疗选择：减瘤治疗还是非减瘤治疗？
Bone Marrow Transplant. 2025 Mar;60(3):326-334. doi: 10.1038/s41409-024-02486-x. Epub 2024 Dec 4.
3
Superior outcome of upfront allogeneic hematopoietic cell transplantation versus hypomethylating agent induction in myelodysplastic syndrome.
与低甲基化药物诱导相比，初治异基因造血细胞移植治疗骨髓增生异常综合征的疗效更佳。
Bone Marrow Transplant. 2024 Sep;59(9):1332-1334. doi: 10.1038/s41409-024-02365-5. Epub 2024 Jul 9.
4
Delayed kidney transplantation after HLA-haploidentical hematopoietic cell transplantation in a young woman with myelodysplastic syndrome with renal failure.一名患有骨髓增生异常综合征并伴有肾衰竭的年轻女性在接受 HLA 单倍体相合造血细胞移植后延迟进行肾移植。
Leuk Res Rep. 2022 Mar 17;17:100302. doi: 10.1016/j.lrr.2022.100302. eCollection 2022.
5
Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia: Who, When, and How?异基因造血干细胞移植治疗急性髓系白血病：谁、何时以及如何移植？
Front Immunol. 2021 May 3;12:659595. doi: 10.3389/fimmu.2021.659595. eCollection 2021.
6
Pre-transplantation cytoreduction does not benefit advanced myelodysplastic syndrome patients after myeloablative transplantation with grafts from family donors.移植前细胞减灭对亲缘供者来源的清髓性移植后进展性骨髓增生异常综合征患者无益。
Cancer Commun (Lond). 2021 Apr;41(4):333-344. doi: 10.1002/cac2.12140. Epub 2021 Feb 10.
7
Existing agents, novel agents, or transplantation for high-risk MDS.高危 MDS 的现有药物、新型药物或移植。
Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):411-417. doi: 10.1182/hematology.2020000125.
8
Pre-transplant cytoreductive therapy can improve overall survival of patients with MDS-AML but not MDS-EB2 receiving HLA-matched sibling donor peripheral blood stem cell transplantation.移植前细胞减灭疗法可改善接受人类白细胞抗原匹配同胞供体外周血干细胞移植的骨髓增生异常综合征伴急性髓系白血病（MDS-AML）患者的总生存期，但对骨髓增生异常综合征伴原始细胞过多-2型（MDS-EB2）患者无效。
Am J Cancer Res. 2020 Apr 1;10(4):1218-1228. eCollection 2020.
9
[Outcomes of 138 myelodysplastic syndrome patients with HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation].138例具有人类白细胞抗原匹配同胞供者的异基因造血干细胞移植的骨髓增生异常综合征患者的结局
Zhonghua Xue Ye Xue Za Zhi. 2020 Feb 14;41(2):132-137. doi: 10.3760/cma.j.issn.0253-2727.2020.02.009.
10
In MDS, is higher risk higher reward?在 MDS 中，风险越高，回报越高吗？
Hematology Am Soc Hematol Educ Program. 2019 Dec 6;2019(1):381-390. doi: 10.1182/hematology.2019000042.